Clinical Report: Advancing Understanding of Secondary Lymphedema Pathophysiology
Overview
This review discusses the application of omics technologies in understanding secondary lymphedema (LE), highlighting the identification of biomarkers and therapeutic targets.
Background
Secondary lymphedema is a chronic condition that arises from lymphatic vessel injury, often due to cancer treatment, surgery, or infection. Understanding the underlying mechanisms is crucial for developing effective interventions. Omics approaches provide a comprehensive view of the biological processes involved in LE.
Data Highlights
Study
Findings
Karaman et al.
Upregulated inflammatory and angiogenesis-related genes in LE arms.
Zamora et al.
Identified upregulated genes including PTX3 and IL6 in LE tissue.
Zhao et al.
Found upregulation of PLA2G2A and PLA2G5 in LE fatty tissue.
Chen et al.
Identified 2025 upregulated and 1285 downregulated genes in LE tissue.
Key Findings
Omics technologies have identified key inflammatory and fibrotic pathways in secondary LE.
Transcriptomic analyses reveal significant gene expression changes in lymphedematous tissues compared to normal tissues.
Specific genes such as IL6 and VEGFC are upregulated in secondary LE.
Current methodologies face limitations in sample diversity and bioinformatics.
Clinical Implications
The findings suggest that integrating omics technologies can lead to better understanding and management of secondary lymphedema. Identifying specific biomarkers may facilitate early diagnosis and targeted therapies.
Conclusion
Advancements in omics approaches hold promise for elucidating the complex pathophysiology of secondary lymphedema, paving the way for improved diagnostic and therapeutic strategies.
by Annica R. Stull-Lane, Xizhao Chen, Abraham J. Book, Radomir Kratchmarov, Sarit Pal, Jinyeon Shin, Gopika Ashokan, Geoffrey E. Hespe, Babak J. Mehrara, Raghu P. Kataru
